ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2689

Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
Abstract Number: 2690

Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
Abstract Number: 2691

Understanding the Impact of Overweight and Obesity on Treatment Response in Psoriatic Arthritis: Results from a Longitudinal Cohort Study
Abstract Number: 2692

Individualized Strength, Mobility and Aerobic Rehabilitation Training in axial Spondyloarthritis (iSMART in axSpA)
Abstract Number: 2693

CAR T-cell Therapy in SLE: A Systematic Review
Abstract Number: 2694

Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus
Abstract Number: 2695

B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents
Abstract Number: 2696

Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
Abstract Number: 2697

A Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-Maintenance Treatment for Class III/IV±V Lupus Nephritis
Abstract Number: 2698

Comparative Efficacy of Tacrolimus-Based Induction Therapy with and without Mycophenolate Mofetil in Lupus Nephritis: A Target Trial Emulation Study
Abstract Number: 2699

Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study
Abstract Number: 2700

Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome
Abstract Number: 2701

Ophthalmic Manifestations of Relapsing Polychondritis
Abstract Number: 2702

Diagnostic Performance of Vascular Ultrasound in Giant Cell Arteritis – A Single Center Experience
Abstract Number: 2703

Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].